Literature DB >> 8636276

Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.

K Nakayama1, S Fukumoto, S Takeda, Y Takeuchi, T Ishikawa, M Miura, K Hata, M Hane, Y Tamura, Y Tanaka, M Kitaoka, T Obara, E Ogata, T Matsumoto.   

Abstract

Bone and vitamin D metabolism are examined in patients with primary hyperparathyroidism (1 degree HPT), humoral hypercalcemia of malignancy (HHM), and local osteolytic hypercalcemia (LOH) with normal renal function. Among the bone resorption markers, T scores of total deoxypyridinoline (Dpyd) were highest in HHM and were significantly higher than those in 1 degree HPT. Among the formation markers, T scores of osteocalcin (OC) were highest in 1 degree HPT but were negative in HHM. The elevation in total Dpyd was associated with an increase in OC in 1 degree HPT, and the ratios of total Dpyd/OC were similar to those in controls. In contrast, many patients with HHM and LOH exhibited elevated total Dpyd and suppressed OC with increased total Dpyd/OC ratios, but the ratios varied widely. Serum 1,25-dihydroxyvitamin D [1,25(OH)2D] was elevated in 1 degrees HPT but was suppressed in HHM and LOH at any serum Ca levels. These results demonstrate that increased bone resorption is associated with enhanced bone formation in 1 degrees HPT but are uncoupled in many of the HHM and LOH patients, and that total Dpyd/OC ratio can be a useful index to estimate the coupling state of bone. It is suggested that the reduction in serum 1,25(OH)2D cannot be explained by an elevation in serum Ca in HHM and LOH, and that the differences in bone and vitamin D metabolism in HHM and LOH from those in 1 degree HPT may be caused by a common mechanism such as the secretion of some cytokines from tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636276     DOI: 10.1210/jcem.81.2.8636276

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  Emergencies of calcium homeostasis.

Authors:  Jean-Jacques Body; Roger Bouillon
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

2.  A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Linda Prebehala; Caren M Gundberg; Bruce W Hollis; Alessandro Bisello; Adolfo Garcia-Ocaña; Raquel M Carneiro; Andrew F Stewart
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

3.  Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover.

Authors:  Raquel M Carneiro; Linda Prebehalla; Mary Beth Tedesco; Susan M Sereika; Maryann Hugo; Bruce W Hollis; Caren M Gundberg; Andrew F Stewart; Mara J Horwitz
Journal:  J Clin Endocrinol Metab       Date:  2010-02-11       Impact factor: 5.958

4.  Hypercalcemia as Initial Presentation of Metastatic Adenocarcinoma of Gastric Origin: A Case Report and Review of the Literature.

Authors:  Mehandar Kumar; Abhishek Kumar; Vinod Kumar; Supreet Kaur; Michael Maroules
Journal:  J Gastric Cancer       Date:  2016-09-30       Impact factor: 3.720

5.  Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy.

Authors:  Katie N Evans; Harris Taylor; Daniel Zehnder; Mark D Kilby; Judith N Bulmer; Farah Shah; John S Adams; Martin Hewison
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

Review 6.  The multifaceted actions of PTHrP in skeletal metastasis.

Authors:  Fabiana N Soki; Serk In Park; Laurie K McCauley
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

7.  Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma.

Authors:  Sarika B Shivnani; John M Shelton; James A Richardson; Naim M Maalouf
Journal:  Endocr Pract       Date:  2009-04       Impact factor: 3.443

8.  [Tumor-induced hypercalcemia].

Authors:  O Hopfer; A Gawliczek; M G Kiehl
Journal:  Internist (Berl)       Date:  2013-09       Impact factor: 0.743

9.  Hypercalcemia in non-Hodgkin's lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D.

Authors:  A R Gonciulea; Y Wang; D D Bikle; D E Sellmeyer
Journal:  Osteoporos Int       Date:  2021-07-06       Impact factor: 4.507

10.  Hypercalcemia of Malignancy and Colorectal Cancer.

Authors:  Rodolfo J Galindo; Isabela Romao; Ageliki Valsamis; Stuart Weinerman; Yael Tobi Harris
Journal:  World J Oncol       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.